Clinical Trial Update: PediCARE Health Equity Intervention in High-Risk Neuroblastoma [NA]

View source ↗

Summary

The PediCARE health equity trial for high-risk neuroblastoma has been withdrawn. The study was sponsored by Dana-Farber Cancer Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroblastoma, High-risk Neuroblastoma | NA | Status: WITHDRAWN